Cited by 271Gastrointestinal motility and disordersGut microbiota and healthInflammatory Bowel Disease

The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

Open access

Xu, Dabo, Gao, Jun, Gillilland, Merritt, Wu, Xiaoyin, Song, Il, Kao, John Y., Owyang, Chung·2014·Gastroenterology

DOI 10.1053/j.gastro.2013.10.026PMC PMC3939606

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims Rifaximin is used to treat patients with functional gastrointestinal disorders, but little is known about its therapeutic mechanism. We propose that rifaximin modulates the ileal bacterial community, reduces subclinical inflammation of the intestinal mucosa, and improves gut barrier function to reduce visceral hypersensitivity.Methods We induced visceral hyperalgesia in rats, via chronic water avoidance or repeat restraint stressors, and investigated whether rifaximin altered the gut microbiota, prevented intestinal inflammation, and improved gut barrier function. Quantitative polymerase chain reaction (PCR) and 454 pyrosequencing were used to analyze bacterial 16S ribosomal RNA in ileal contents from the rats. Reverse transcription, immunoblot, and histologic analyses were used to evaluate levels of cytokines, the tight junction protein occludin, and mucosal inflammation, respectively. Intestinal permeability and rectal sensitivity were measured.Results Water avoidance and repeat restraint stress each led to visceral hyperalgesia, accompanied by mucosal inflammation and impaired mucosal barrier function. Oral rifaximin altered the composition of bacterial communities in the ileum (Lactobacillus species became the most abundant) and prevented mucosal inflammation, impairment to intestinal barrier function, and visceral hyperalgesia in response to chronic stress. Neomycin also changed the composition of the ileal bacterial community (Proteobacteria became the most abundant species). Neomycin did not prevent intestinal inflammation or induction of visceral hyperalgesia induced by water avoidance stress.Conclusions Rifaximin alters the bacterial population in the ileum of rats, leading to a relative abundance of Lactobacillus. These changes prevent intestinal abnormalities and visceral hyperalgesia in response to chronic psychological stress.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2013.10.026

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 21,481
Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine
Hooper, L. V., Wong, M. H., Thelin, A., Hansson, L., Falk, P. G., & Gordon, J. I. (2001) · Science · doi:10.1126/science.291.5505.881 · Cited by 2,202
Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation
Bailey, M. T., Dowd, S. E., Galley, J. D., Hufnagle, A. R., Allen, R. G., & Lyte, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.023 · Cited by 1,123
Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses
O'Mahony, S. M., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A.-M., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.026 · Cited by 1,069
Global and Deep Molecular Analysis of Microbiota Signatures in Fecal Samples From Patients With Irritable Bowel Syndrome
Rajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Intestinal barrier function in health and gastrointestinal disease
Camilleri, M., Madsen, K., Spiller, R., Van Meerveld, B. G., & Verne, G. N. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01921.x · Cited by 908
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis
Brun, P., Castagliuolo, I., Leo, V. D., Buda, A., Pinzani, M., Palù, G., & Martines, D. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2006 · Cited by 880
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835

Flagged first, then by citations

Show all 47 references

2 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

Zelena, 2003, Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint, Am J Physiol Endocrinol Metab, 285, E1110, 10.1152/ajpendo.00219.2003 · DOI
Schloss, 2009, Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities, Appl Environ Microbiol, 75, 7537, 10.1128/AEM.01541-09 · DOI
Coutinho, 2002, Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, G307, 10.1152/ajpgi.00240.2001 · DOI
Bradesi, 2005, Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, G42, 10.1152/ajpgi.00500.2004 · DOI

Sorted by citations

Items 101–200 of 270

Structural and functional alterations in the colonic microbiome of the rat in a model of stress induced irritable bowel syndrome
Fourie, N. H., Wang, D., Abey, S. K., Creekmore, A. L., Hong, S., Martin, C. G., Wiley, J. W., & Henderson, W. A. (2017) · Gut Microbes · doi:10.1080/19490976.2016.1273999 · Cited by 40
Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats
Yu, Z., Cen, Y.-X., Wu, B.-H., Cheng, W., Xiong, F., Li, D., Liu, T.-T., Luo, M., Guo, L., Li, Y., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3956 · Cited by 41
Obesity and Risk of Small Intestine Bacterial Overgrowth: A Systematic Review and Meta-Analysis
Wijarnpreecha, K., Werlang, M. E., Watthanasuntorn, K., Panjawatanan, P., Cheungpasitporn, W., Gómez, V., Lukens, F., & Ungprasert, P. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05887-x · Cited by 41
Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Han, J. W., Kim, D. I., Nam, H. C., Chang, U. I., Yang, J. M., & Song, D. S. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0082 · Cited by 41
Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome
Singh, P., & Lembo, A. J. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.03.003 · Cited by 39
Repeated water avoidance stress induces visceral hypersensitivity: Role of interleukin‐1, interleukin‐6, and peripheral corticotropin‐releasing factor
Nozu, T., Miyagishi, S., Nozu, R., Takakusaki, K., & Okumura, T. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13787 · Cited by 39
Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia
Wang, C., & Fang, X. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm20175 · Cited by 43
Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome
Mujagic, Z., Jonkers, D. M. A. E., Ludidi, S., Keszthelyi, D., Hesselink, M., Weerts, Z. Z. R. M., Kievit, R. N., Althof, J. F., Leue, C., Kruimel, J. W., et al. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13137 · Cited by 41
Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship
Gao, J., Gillilland, M. G., & Owyang, C. (2014) · Gut Microbes · doi:10.4161/gmic.32130 · Cited by 39
Self-citation
Synergic Interaction of Rifaximin and Mutaflor (Escherichia coliNissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats
DEMBINSKI, A. B., Warzecha, Z., Ceranowicz, P., Dembiński, M., Cieszkowski, J., Gosiewski, T., Bulanda, M., Kuśnierz‐Cabala, B., Gałązka, K., & Konturek, P. C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/3126280 · Cited by 38
Chronic stress-associated visceral hyperalgesia correlates with severity of intestinal barrier dysfunction
Creekmore, A. L., Hong, S., Zhu, S., Xue, J., & Wiley, J. W. (2018) · Pain · doi:10.1097/j.pain.0000000000001271 · Cited by 38
Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis
Takakura, W., Rezaie, A. R., Chey, W. D., Wang, J., & Pimentel, M. (2024) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22187 · Cited by 37
Intestinal barrier in chronic gut and liver diseases: Pathogenesis and therapeutic targets
Zhang, Y., Liu, Y., Liang, X., Wen, Y., Zhao, J., He, Y., Xie, Q., & Xie, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.028 · Cited by 40
Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases
DuPont, H. L. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.04.016 · Cited by 40
Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Scarpellini, E., Lupo, M., Iegri, C., Gasbarrini, A., Santis, A. D., & Tack, J. F. (2015) · Reviews on Recent Clinical Trials · doi:10.2174/1574887109666141216104334 · Cited by 36
Multi-omics for biomarker approaches in the diagnostic evaluation and management of abdominal pain and irritable bowel syndrome: what lies ahead
Shin, A., & Kashyap, P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2195792 · Cited by 34
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
Kane, J., & Ford, A. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1140571 · Cited by 38
Rifaximin‐altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials
Kawaguchi, T., Suzuki, F., Imamura, M., Murashima, N., Yanase, M., Mine, T., Fujisawa, M., Sato, I., Yoshiji, H., Okita, K., et al. (2018) · Hepatology Research · doi:10.1111/hepr.13300 · Cited by 36
Histone H3K9 methylation regulates chronic stress and IL‐6–induced colon epithelial permeability and visceral pain
Wiley, J. W., Zong, Y., Zheng, G., Zhu, S., & Hong, S. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13941 · Cited by 35
Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia
Shah, A., Gurusamy, S. R., Hansen, T. J., Callaghan, G., Talley, N. J., Koloski, N. A., Walker, M. M., Jones, M. P., Morrison, M., & Holtmann, G. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07149-1 · Cited by 34
Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity
Ranhotra, H. S., Flannigan, K. L., Brave, M., Mukherjee, S., Lukin, D. J., Hirota, S. A., & Mani, S. (2016) · Nuclear Receptor Research · doi:10.11131/2016/101199 · Cited by 37
New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
Bajaj, J. S., Barbara, G., DuPont, H. L., Mearin, F., Gasbarrini, A., & Tack, J. F. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.04.020 · Cited by 32
Effect of chronic stress on tumorigenesis and development
Wang, C., Shen, Y., Ni, J., Hu, W., & Yang, Y. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04455-3 · Cited by 29
Isomalto-oligosaccharides ameliorate visceral hyperalgesia with repair damage of ileal epithelial ultrastructure in rats
Wang, W., Xin, H., Fang, X., Dou, H., Liu, F., Huang, D., Han, S., Fei, G., Zhu, L., Zha, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175276 · Cited by 31
Pathophysiological Commonality Between Irritable Bowel Syndrome and Metabolic Syndrome: Role of Corticotropin-releasing Factor-Toll-like Receptor 4-Proinflammatory Cytokine Signaling
Nozu, T., & Okumura, T. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21002 · Cited by 31
Activation of Intestinal Human Pregnane X Receptor Protects against Azoxymethane/Dextran Sulfate Sodium–Induced Colon Cancer
Cheng, J., Fang, Z.-Z., Nagaoka, K., Okamoto, M., Qu, A., Tanaka, N., Kimura, S., & Gonzalez, F. J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.215913 · Cited by 30
Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
Zhuang, X., Tian, Z., Luo, M., & Xiong, L. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01336-6 · Cited by 30
Sex‐based differences in fecal short‐chain fatty acid and gut microbiota in irritable bowel syndrome patients
Sun, Q. H., Liu, Z. J., Zhang, L., Wei, H., Song, L. J., Zhu, S. W., He, M. B., & Duan, L. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12988 · Cited by 34
Rifaximin ameliorates depression-like behaviour in chronic unpredictable mild stress rats by regulating intestinal microbiota and hippocampal tryptophan metabolism
Cheng, S., Zhu, Z., Li, H., Wang, W., Jiang, Z., Pan, F., Liu, D., Ho, R., & Ho, C. S. H. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.086 · Cited by 32
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic
Fornai, M., Antonioli, L., Pellegrini, C., Colucci, R., Sacco, D., Tirotta, E., Natale, G., Bartalucci, A., Flaibani, M., Renzulli, C., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.031 · Cited by 29
Critical Evaluation of Animal Models of Gastrointestinal Disorders
Johnson, A. C., & Meerveld, B. G. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2016_120 · Cited by 29
Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats
Nozu, T., Miyagishi, S., Kumei, S., Nozu, R., Takakusaki, K., & Okumura, T. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.056 · Cited by 28
Gut microbiota and physiologic bowel 18F-FDG uptake
Kang, J. Y., Kim, H.-N., Chang, Y., Yun, Y., Ryu, S., Shin, H., & Kim, H. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0318-8 · Cited by 28
Neomycin and bacitracin reduce the intestinal permeability in mice and increase the expression of some tight-junction proteins
Nevado, R., Forcén, R., Layunta, E., Murillo, M. D., & Grasa, L. (2015) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2015.3868/2015 · Cited by 27
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease
Lopetuso, L. R., Napoli, M., Rizzatti, G., & Gasbarrini, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1483333 · Cited by 27
Enterochromaffin Cells: Sentinels to Gut Microbiota in Hyperalgesia?
Xu, X., Chen, R., Zhan, G., Wang, D., Tan, X., & Xu, H. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.760076 · Cited by 31
Gut microbiota and its role in stress-induced hyperalgesia: Gender-specific responses linked to different changes in serum metabolites
Xu, X., Zhan, G., Chen, R., Wang, D., Guan, S., & Xu, H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106129 · Cited by 26
Lactobacillus rhamnosus strain JB ‐1 reverses restraint stress‐induced gut dysmotility
West, C. L., Wu, R., Wong, A., Stanisz, A. M., Yan, R. R., Min, K. K. H., Pasyk, M., Neufeld, K. M., Karamat, M. I., Foster, J. A., et al. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12903 · Cited by 31
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation
Ponziani, F. R., Pecere, S., Lopetuso, L. R., Scaldaferri, F., Cammarota, G., & Gasbarrini, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1186639 · Cited by 24
Bile acid–gut microbiota crosstalk in irritable bowel syndrome
Gu, Y., Li, L., Yang, M., Liu, T., Song, X., Qin, X., Xu, X. J., Liu, J., Wang, B., & Cao, H. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2058353 · Cited by 26
Oxytocin antagonist induced visceral pain and corticotropin-releasing hormone neuronal activation in the central nucleus of the amygdala during colorectal distention in mice
Tsushima, H., Zhang, Y., Muratsubaki, T., Kanazawa, M., & Fukudo, S. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.04.011 · Cited by 22
UEG Week 2016 Poster Presentations
Dargienė, G., Kupčinskas, J., Jonaitis, L. V., Urbonas, V., Aužbikienė, R., Frandsen, T. H., Kučinskienė, R., Kaduševičius, E., Kupčinskas, L., & Andersen, L. P. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616663689 · Cited by 26
Effects of Rifaximin on Central Responses to Social Stress—a Pilot Experiment
Wang, H., Braun, C., & Enck, P. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0627-2 · Cited by 24
Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms
Yu, L. C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123153 · Cited by 29
Does low‐dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study
Zeng, X., Tang, X., Sheng, X., Ni, W., Xin, H. G., Chen, W. Z., Jiang, C., Lin, Y., Shi, J. G., Shi, B., et al. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12294 · Cited by 23
Does stress induce bowel dysfunction?
Chang, Y.-M., Zaatari, M. E., & Kao, J. Y. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.911659 · Cited by 23
Self-citation
The Usefulness of Symptom-based Subtypes of Functional Dyspepsia for Predicting Underlying Pathophysiologic Mechanisms and Choosing Appropriate Therapeutic Agents
Lee, K. J. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21042 · Cited by 22
Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a
Ke, W., Wang, Y., Huang, S., Liu, S., Zhu, H., Xie, X., Yang, H., Lu, Q., Gan, J., He, G., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12312 · Cited by 21
TRPV6 deficiency attenuates stress and corticosterone-mediated exacerbation of alcohol-induced gut barrier dysfunction and systemic inflammation
Meena, A. S., Shukla, P. K., Rao, R., Canelas, C., Pierre, J. F., & Rao, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093584 · Cited by 21
Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders
Yuan, Y., Wang, X., Xu, X., Liu, Y., CanCan, L., Meng, Y., Yang, Y., & Ma, Z. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00374 · Cited by 21
Chronic Psychological Stress Alters Gene Expression in Rat Colon Epithelial Cells Promoting Chromatin Remodeling, Barrier Dysfunction and Inflammation
Wiley, J. W., Higgins, G. A., & Hong, S. (2022) · PeerJ · doi:10.7717/peerj.13287 · Cited by 21
Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
Schey, R., Iorio, N., & Malik, Z. A. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s67231 · Cited by 21
A role for gut microbiota in early-life stress-induced widespread muscle pain in the adult rat
Green, P. G., Álvarez, P., & Levine, J. D. (2021) · Molecular Pain · doi:10.1177/17448069211022952 · Cited by 20
Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis
Bogatic, D., Bryant, R. V., Lynch, K. D., & Costello, S. P. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17251 · Cited by 19
The effects of different stress on intestinal mucosal barrier and intestinal microecology were discussed based on three typical animal models
Guo, J., Lou, X., Gong, W., Bian, J., Liao, Y., Wu, Q., Jiao, Q., & Zhang, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.953474 · Cited by 19
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
Laterza, L., Ianiro, G., Scoleri, I., Landi, R., Bruno, G., Scaldaferri, F., Gaetani, E., Campanale, M., & Gasbarrini, A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1007951 · Cited by 18
Neonatal Maternal Deprivation Followed by Adult Stress Enhances Adrenergic Signaling to Advance Visceral Hypersensitivity
Du, W., Hu, S., Li, X., Zhang, P., Jiang, X., Yu, S.-P., & Xu, G. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0318-3 · Cited by 18
Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome
Bruzzese, E., Pesce, M., Sarnelli, G., & Guarino, A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1488964 · Cited by 18
A clinical primer of the role of gut microbiome in health and disease
Yang, A. L., & Kashyap, P. (2015) · Tropical Gastroenterology · doi:10.7869/tg.238 · Cited by 16
Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome
Wang, Y., Zheng, F., Liu, S., & Luo, H. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/9759138 · Cited by 16
Impact of 4-epi-oxytetracycline on the gut microbiota and blood metabolomics of Wistar rats
Han, H., Xiao, H., Zhang, K., & Lü, Z. (2016) · Scientific Reports · doi:10.1038/srep23141 · Cited by 16
Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway
Qiu, T. H., Zhu, X., Wu, J., Hong, W., Hu, W., & Fang, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-92282-4 · Cited by 15
Rodent Model of Irritable Bowel Syndrome
Wang, Y., Bi, Z., Wang, E., Sun, B., Zheng, Y., Zhong, L. L. D., & Yuan, J. (2017) · International Journal of Gastroenterology Disorders & Therapy · doi:10.15344/2393-8498/2017/131 · Cited by 14
Campylobacter infection and the link with Irritable Bowel Syndrome:on the pathway towards a causal association
Takakura, W., Kudaravalli, P., Chatterjee, C., Pimentel, M., & Riddle, M. S. (2022) · Pathogens and Disease · doi:10.1093/femspd/ftac003 · Cited by 16
Upregulated adenosine 2A receptor accelerates post-infectious irritable bowel syndrome by promoting CD4+ T cells’ T helper 17 polarization
Dong, L., Ma, Z., Fu, J., Huang, B.-L., Liu, F., Sun, D., & Cheng, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2955 · Cited by 14
Research trends in the field of the gut-brain interaction: Functional dyspepsia in the spotlight – An integrated bibliometric and science mapping approach
Zhang, T., Zhang, B., Ma, X., Zhang, J., Wei, Y., Wang, F., & Tang, X. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1109510 · Cited by 15
Update on the Role of Rifaximin in Digestive Diseases
Dumitrascu, D. L., Бакулин, И. Г., Berzigotti, A., Cravo, M. L., Gombošová, L., Lukáš, M., Pietrzak, A. M., Remes-Troche, J. M., Romero‐Gómez, M., Amieva‐Balmori, M., et al. (2023) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4871 · Cited by 12
Rifaximin alleviates intestinal barrier disruption and systemic inflammation via the PXR/NFκB/MLCK pathway and modulates intestinal Lachnospiraceae abundance in heat-stroke mice
Du, L., Jiang, W., Zhu, X., Zhu, L., Fan, Y., & Jiang, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113462 · Cited by 16
Probiotic Yeast from Miso Ameliorates Stress-Induced Visceral Hypersensitivity by Modulating the Gut Microbiota in a Rat Model of Irritable Bowel Syndrome
Sugihara, N., Okada, Y., Tomioka, A., Ito, S., Tanemoto, R., Nishii, S., Mizoguchi, A., Inaba, K., Hanawa, Y., Horiuchi, K., et al. (2023) · Gut and Liver · doi:10.5009/gnl220100 · Cited by 12
Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder
Zheng, X., Zhang, X., Wang, G., & Hao, H. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.015 · Cited by 12
Mechanisms underlying the effects of stress on tumorigenesis and metastasis (Review)
Zhang, Z., Wang, Y., & Li, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4570 · Cited by 13
Update in diagnosis and management of irritable bowel syndrome
Hung, T.-H., Wang, C.-Y., & Lee, H.-F. (2023) · Tzu-Chi Medical Journal · doi:10.4103/tcmj.tcmj_104_23 · Cited by 15
Early treatment with rifaximin during epileptogenesis reverses gut alterations and reduces seizure duration in a mouse model of acquired epilepsy
Kebede, V., Ravizza, T., Balosso, S., Sapia, R. D., Canali, L., Soldi, S., Galletti, S., Papazlatani, C. V., Karas, P. A., Vasileiadis, S., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.04.007 · Cited by 13
Restraint stress induced gut dysmotility is diminished by a milk oligosaccharide (2′-fucosyllactose) in vitro
Farhin, S., Wong, A., Delungahawatta, T., Amin, J. Y., Bienenstock, J., Buck, R. H., & Kunze, W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215151 · Cited by 11
Role of peripheral inflammation in minimal hepatic encephalopathy
Llansola, M., Izquierdo‐Altarejos, P., Montoliú, C., Mincheva, G., Palomares-Rodriguez, A., Pedrosa, M. A., Arenas, Y. M., & Felipo, V. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01417-5 · Cited by 10
Rifaximin alleviates irinotecan-induced diarrhea in mice model
Huang, C.-Y., Lan, H., Bai, M., Chen, J., Xu, S., Sun, Q., Chen, Q., Mao, W. B., Jiang, J. F., & Zhu, J. Y. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2429029 · Cited by 10
Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome
Chuah, K. H., Loo, Q. Y., Loh, A. J. C., Leong, J. Y., Chan, W. L., Khoo, X. H., Wong, K. L., Panirsheeluam, S., Natarajan, V., Ng, A. K., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70420 · Cited by 10
Obesity Exacerbates Irritable Bowel Syndrome-Related Sleep and Psychiatric Disorders in Women With Polycystic Ovary Syndrome
Tseng, P., Chiu, H., Tu, C., Wu, M., Ho, H., & Chen, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.779456 · Cited by 12
Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome
Algera, J. P., Törnblom, H., & Simrén, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102284 · Cited by 10
Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
Torre, A., Córdova‐Gallardo, J., & Munari, A. C. F. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s425292 · Cited by 10
Susceptibilidad a la rifaximina y otros antimicrobianos de bacterias aisladas en pacientes con infecciones gastrointestinales agudas en el sureste de México
Novoa-Farías, O., Frati-Munari, A. C., Peredo, M. A., Flores-Juárez, S., Novoa-García, O., Galicia-Tapia, J., & Romero-Carpio, C. E. (2017) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2016.10.006 · Cited by 10
Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
Zhang, S., Hong, G., Li, G., Qian, W., Jin, Y. T., & Hou, X. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02772-6 · Cited by 9
Allergenicity determination of Turbot parvalbumin for safety of fish allergy via dendritic cells, RBL‐2H3 cell and mouse model
Wu, Y., Lin, H., Lü, Y., Huang, Y., Dasanayaka, B. P., Ahmed, I., Chen, G., Chen, Y., & Li, Z. (2021) · European Food Research and Technology · doi:10.1007/s00217-021-03763-5 · Cited by 9
Fish allergens of turbot ( Scophthalmus maximus ) parvalbumin triggers food allergy via inducing maturation of bone marrow derived dendritic cells and driving Th2 immune response
Wu, Y., Lü, Y., Huang, Y., Lin, H., Xu, M., Ahmed, I., Chen, G., Chen, Y., & Li, Z. (2022) · Food & Function · doi:10.1039/d1fo04070g · Cited by 9
Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico
Novoa-Farías, O., Frati-Munari, A. C., Peredo, M. A., Flores-Juárez, S., Novoa-García, O., Galicia-Tapia, J., & Romero-Carpio, C. E. (2017) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2017.03.012 · Cited by 9
Background Intestinal 18F-FDG Uptake Is Related to Serum Lipid Profile and Obesity in Breast Cancer Patients
Yoon, H., Kim, H., Yun, Y., Kim, Y., Ha, A.-N., Kim, H., & Kim, B. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141473 · Cited by 9
Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats
Pekary, A. E., & Sattin, A. (2022) · BMC Neuroscience · doi:10.1186/s12868-022-00694-z · Cited by 9
Gastroparesis syndromes: emerging drug targets and potential therapeutic opportunities
Naing, L. Y., Heckroth, M. A., Mathur, P., & Abell, T. L. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2186222 · Cited by 8
Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut–Liver Axis and Epiregulin–IL-8-Associated Angiogenesis
Nishimura, N., Kaji, K., Nishimura, N., Hanatani, J., Nakatani, T., Oyama, M., Shibamoto, A., Tsuji, Y., Kitagawa, K., Sato, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146710 · Cited by 8
The emerging role of hypoxia and environmental factors in inflammatory bowel disease
Villareal, L., & Xue, X. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae004 · Cited by 9
Electroacupuncture alleviates water avoidance stress-induced irritable bowel syndrome in mice by improving intestinal barrier functions and suppressing the expression of inflammatory cytokines.
Mengzhu, S., Yujie, Z., Song, Y., Guo, J., Yuhang, W., Chen, X., Dongmei, G. U., Jianhua, S., & Pei, L. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.2023.03.001 · Cited by 8
Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
Yoon, K., Kim, N., Lee, J. Y., Oh, D. H., Seo, A. Y., Yun, C. Y., Yoon, H., Shin, C. M., Park, Y. S., & Lee, D. H. (2018) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2018.72.3.121 · Cited by 8
Preclinical models of irritable bowel syndrome
López‐Gómez, L., Bagüés, A., Uranga, J. A., & Abalo, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821324-7.00012-5 · Cited by 8
Effects of Vitamin D3 on Intestinal Flora in a Mouse Model of Inflammatory Bowel Disease Treated with Rifaximin
Gu, Z., Duan, M., Sun, Y., Leng, T., Xu, T., Gu, Y., Gu, Z., Lin, Z., Yang, L., & Ji, M. (2020) · Medical Science Monitor · doi:10.12659/msm.925068 · Cited by 8
The Leaky Gut and Human Diseases: “Can’t Fill the Cup if You Don’t Plug the Holes First”
Compare, D., Sgamato, C., Rocco, A., Coccoli, P., Ambrosio, C., & Nardone, G. (2024) · Digestive Diseases · doi:10.1159/000540379 · Cited by 9
Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice
Ferrer, M., Aguilera, M., & Martı́nez, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020500 · Cited by 7
Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications
Crisan, I. M., & Dumitrascu, D. L. (2014) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-269 · Cited by 7
6-Shogaol Derived from Ginger Inhibits Intestinal Crypt Stem Cell Differentiation and Contributes to Irritable Bowel Syndrome Risk
Zhao, B., Ye, J., Zhao, W., Liu, X., Lan, H., Sun, J., Chen, J., Cai, X., Wei, Q., Zhou, Q., et al. (2024) · Research · doi:10.34133/research.0524 · Cited by 6
Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study
Ivashkin, V. T., Shifrin, O. S., Maslennikov, R. V., Poluektova, E., Korolev, A., Kudryavtseva, A. V., Krasnov, G. S., Benuni, N., & Barbara, G. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02690-x · Cited by 6
Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats
Zhang, J., Zhang, C., Zhang, T., Zhang, L., & Duan, L. (2023) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22182 · Cited by 6

Authors: Xu, D., Gao, J., Gillilland, M., Wu, X., Song, I., Kao, J. Y., & Owyang, C.
Affiliations: University of Michigan (US)
Corresponding author: Owyang, Chung
ORCID: Gao, Jun
Gillilland, Merritt
Wu, Xiaoyin
Kao, John Y.
Owyang, Chung
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2014-02
Volume: 146
Issue: 2
Pages: 484-496.e4
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2013.10.026
PMC: PMC3939606
OpenAlex: W2125894152
Cited by: 271
References: 47
Citations by year: 2026: 12 · 2025: 17 · 2024: 15 · 2023: 26 · 2022: 21 · 2021: 30 · 2020: 11 · 2019: 22 · 2018: 27 · 2017: 30 · 2016: 24 · 2015: 21 · 2014: 15
FWCI: 18.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (P30DK34933, R01DK058913)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords: rifaximin, gut microbiota, visceral hypersensitivity, intestinal barrier function, Lactobacillus, neomycin, chronic psychological stress, water avoidance stress, occludin, intestinal permeability, rectal sensitivity, functional gastrointestinal disorders
MeSH terms: Rifaximin, Administration, Oral, Animals, DNA, Bacterial, Drug Administration Schedule, Gastrointestinal Agents, Hyperalgesia, Ileitis, Ileum, Immunohistochemistry, Intestinal Mucosa, Male, Neomycin, Restraint, Physical, Rifamycins, Stress, Psychological, Blotting, Western, Biomarkers, Cytokines, Rats, Wistar, Sequence Analysis, DNA, Reverse Transcriptase Polymerase Chain Reaction, Rats, Occludin, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks